AUG 30, 2016 08:00 AM PDT

From millions to billions to trillions - translating your cell discovery into a cell product

Speakers
  • Vice President, Technology and Director, BridGE at CCRM, Canada
    Biography
      Nick is VP, Technology, and Director, BridGE at CCRM. A bioprocess engineering by training, his career has focused on the development of manufacturing process for cellular therapies. Following undergraduate studies in New Zealand he gained his PhD in Australia, did a post-doc in Switzerland, returned to Australia as a research Team Leader, and in 2011 relocated to Canada to join CCRM.

    Abstract:
    A key aspect of translating great scientific discoveries to commercially viable cell therapies is the establishment of robust manufacturing processes that can produce the right quantity of cells, of the right quality, at the right cost, at the right time. In many instances a significant challenge lies in moving from the generation of millions of cells in the research lab to trillions of cells in compliance with regulatory requirements and Good Manufacturing Practices. There is no single path to achieving this, but establishing your vision early and asking the right questions can build a solid foundation from which to pursue future success. This presentation will explore some of these early considerations and why they are important.

    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    OCT 19, 2017 08:00 AM PDT
    C.E. CREDITS
    OCT 19, 2017 08:00 AM PDT
    DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
    NOV 15, 2018 10:00 AM PST
    C.E. CREDITS
    NOV 15, 2018 10:00 AM PST
    DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
    JUL 25, 2017 09:00 AM PDT
    JUL 25, 2017 09:00 AM PDT
    EVENT DETAILS:DATE: July 25, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series.  As a thought-leader in science...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    Loading Comments...